FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:1227-1229 November 3, 1994 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

A quarter of a century ago, Jean Berger, using recently developed immunofluorescence methods, discovered diffuse mesangial deposits of IgA on light microscopy of kidneys with focal, glomerular lesions.¹ IgA nephropathy is now the most common form of glomerulonephritis throughout the world, accounting for up to 10 percent of patients treated for end-stage renal disease.² Patients with IgA nephropathy have better long-term outcomes than those with other forms of glomerulonephritis; their frequency of end-stage renal disease is 13 to 20 percent 10 years after diagnosis and 25 to 34 percent 20 years after diagnosis.³ As in most other forms of glomerulonephritis, . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Donadio, J. V Jr (2000). Use of fish oil to treat patients with immunoglobulin A nephropathy1. Am. J. Clin. Nutr. 71: 373S-375S [Abstract] [Full Text]  
• DONADIO, J. V. JR., GRANDE, J. P., BERGSTRALH, E. J., DART, R. A., LARSON, T. S., SPENCER, D. C. (1999). The Long-Term Outcome of Patients with IgA Nephropathy Treated with Fish Oil in a Controlled Trial. J. Am. Soc. Nephrol. 10: 1772-1777 [Abstract] [Full Text]  
• Boumpas, D T, Balow, J E (1998). Outcome criteria for lupus nephritis trials: A critical overview. Lupus 7: 622-629 [Abstract]  
• Piette, W. W. (1997). What Is Schonlein-Henoch Purpura, and Why Should We Care?. Arch Dermatol 133: 515-518 [Abstract]